14 July 2005

Contents

Conference reports

• Reduced replicative capacity of M184V explains benefit of 3TC monotherapy compared to stopping all drugs

• Interaction between tenofovir and ddI in triple-nucleoside combinations: role of M184V in explaining resistance on failure

• Predicting clinical responses to ddI from genotypic resistance

• Under-detection of transmission of transmitted resistance and impact on treatment response

• Risk of death in UK after diagnosis of 3-class resistance

Antiretrovirals

• TMC-114 to be submitted for registration based on Phase 2b trial results: expanded access expected in UK in Autumn 2005

• Tipranavir (Aptivus) approved in US

• FDA fast track designation for CCR5 inhibitor vicriviroc (SCH-D)

• Pfizer discontinues development of capravirine

Treatment access

• Six Indian generic ARVs are given FDA tentative approval

• Methadone and buprenorphine added to WHO list of essential medicines

• MSF’s pricing guide to purchasing ARVs: 8th edition online

• WHO 3 by 5 progress report

Pregnancy

• Use of T-20 in pregnancy: case study shows transmission occurred in highly treatment experienced mother with multiple-drug resistance

• Further reading on nevirapine resistance

Vaccines and microbicides

• Human Papilloma Virus vaccines – a review of advances in the development of HPV vaccines

Other news

• CDC estimate over 1 million HIV-positive people in US

• Newly diagnosed HIV infection – review in UK and Ireland

• Re-emergence of syphilis in the UK: the new epidemic phases

• Prescription of heroin is less costly for society

On the web

• Medscape full text articles

• HIV inSite Knowledge Base